recombinant granulocyte macrophage colony stimulating factors

Summary

Summary: Granulocyte-macrophage colony-stimulating factors prepared by recombinant DNA technology.

Top Publications

  1. ncbi Potential roles of extracellular signal-regulated kinase but not p38 during myeloid differentiation of U937 cells stimulated by cytokines: augmentation of differentiation via prolonged activation of extracellular signal-regulated kinase
    Emiko Okuma
    Department of Hematology, Research Institute, International Medical Center of Japan, Tokyo, Japan
    Exp Hematol 30:571-81. 2002
  2. ncbi Transduction of CD34+ cells with lentiviral vectors enables the production of large quantities of transgene-expressing immature and mature dendritic cells
    P Salmon
    Department of Genetics and Microbiology, Faculty of Medicine, Geneva University Hospital, Switzerland
    J Gene Med 3:311-20. 2001
  3. ncbi Hematopoietic growth factors in myelodysplastic syndromes
    Victoria S Blinder
    Weill Medical College of Cornell University, Starr Building, Room 340A, 520 East 70th Street, New York, NY 10021, USA
    Curr Hematol Rep 2:453-8. 2003
  4. ncbi Thrombopoietin stimulates ex vivo expansion of mature neutrophils in the early stages of differentiation
    Y Terada
    Clinical Hematology and Clinical Diagnostics, Graduate School of Medicine, Osaka City University, 1 4 3 Asahi machi, Abeno Ku, 545 8585 Osaka, Japan
    Ann Hematol 82:671-6. 2003
  5. ncbi Functional repertoire of dendritic cells generated in granulocyte macrophage-colony stimulating factor and interferon-alpha
    Silvia Della Bella
    Dipartmento di Scienze e Technologie Biomediche, Cattedra di Immunologia, Universita degli Studi di Milano, L I T A, Via Fratelli Cervi 93, 20090 Segrate, Milan, Italy
    J Leukoc Biol 75:106-16. 2004
  6. ncbi IFN-alpha promotes the rapid differentiation of monocytes from patients with chronic myeloid leukemia into activated dendritic cells tuned to undergo full maturation after LPS treatment
    Lucia Gabriele
    Istituto Superiore di Sanita, Laboratory of Virology, Viale Regina Elena 299, 00161 Rome, Italy
    Blood 103:980-7. 2004
  7. ncbi Use of myeloid colony-stimulating factors in neonates with septicemia
    Hilton M Bernstein
    University of South Florida Children s Research Institute, All Children s Hospital, St Petersburg, Florida 33701, USA
    Curr Opin Pediatr 14:91-4. 2002
  8. ncbi Use of hematopoietic growth factors in elderly patients receiving cytotoxic chemotherapy
    C Bokemeyer
    Abteilung Hamatologie, Onkologie, Rheumatologie und Immunologie, Medizinische Universitätsklinik Tübingen, Germany
    Onkologie 25:32-9. 2002
  9. ncbi The role of colony-stimulating factors and granulocyte transfusion in treatment options for neutropenia in children with cancer
    Der Cherng Liang
    Division of Hematology Oncology, Department of Pediatrics, Mackay Memorial Hospital, Taipei, Taiwan
    Paediatr Drugs 5:673-84. 2003
  10. ncbi Notch ligands, Delta-1 and Delta-4 suppress the self-renewal capacity and long-term growth of two myeloblastic leukemia cell lines
    Shuji Tohda
    Department of Laboratory Medicine, Tokyo Medical and Dental University, Tokyo 113 8519, Japan
    Int J Oncol 22:1073-9. 2003

Detail Information

Publications160 found, 100 shown here

  1. ncbi Potential roles of extracellular signal-regulated kinase but not p38 during myeloid differentiation of U937 cells stimulated by cytokines: augmentation of differentiation via prolonged activation of extracellular signal-regulated kinase
    Emiko Okuma
    Department of Hematology, Research Institute, International Medical Center of Japan, Tokyo, Japan
    Exp Hematol 30:571-81. 2002
    ....
  2. ncbi Transduction of CD34+ cells with lentiviral vectors enables the production of large quantities of transgene-expressing immature and mature dendritic cells
    P Salmon
    Department of Genetics and Microbiology, Faculty of Medicine, Geneva University Hospital, Switzerland
    J Gene Med 3:311-20. 2001
    ..CONCLUSION: The transduction of a small number of CD34+ cells with minimal doses of lentivector may allow for the production of a large number of DC expressing selected antigens useful for immunotherapy...
  3. ncbi Hematopoietic growth factors in myelodysplastic syndromes
    Victoria S Blinder
    Weill Medical College of Cornell University, Starr Building, Room 340A, 520 East 70th Street, New York, NY 10021, USA
    Curr Hematol Rep 2:453-8. 2003
    ..This paper reviews the role of hematopoietic growth factors in the treatment of MDS...
  4. ncbi Thrombopoietin stimulates ex vivo expansion of mature neutrophils in the early stages of differentiation
    Y Terada
    Clinical Hematology and Clinical Diagnostics, Graduate School of Medicine, Osaka City University, 1 4 3 Asahi machi, Abeno Ku, 545 8585 Osaka, Japan
    Ann Hematol 82:671-6. 2003
    ..These results suggest that TPO regulates the proliferation and differentiation of neutrophils in the early stages, but not the late stages, of differentiation...
  5. ncbi Functional repertoire of dendritic cells generated in granulocyte macrophage-colony stimulating factor and interferon-alpha
    Silvia Della Bella
    Dipartmento di Scienze e Technologie Biomediche, Cattedra di Immunologia, Universita degli Studi di Milano, L I T A, Via Fratelli Cervi 93, 20090 Segrate, Milan, Italy
    J Leukoc Biol 75:106-16. 2004
    ....
  6. ncbi IFN-alpha promotes the rapid differentiation of monocytes from patients with chronic myeloid leukemia into activated dendritic cells tuned to undergo full maturation after LPS treatment
    Lucia Gabriele
    Istituto Superiore di Sanita, Laboratory of Virology, Viale Regina Elena 299, 00161 Rome, Italy
    Blood 103:980-7. 2004
    ....
  7. ncbi Use of myeloid colony-stimulating factors in neonates with septicemia
    Hilton M Bernstein
    University of South Florida Children s Research Institute, All Children s Hospital, St Petersburg, Florida 33701, USA
    Curr Opin Pediatr 14:91-4. 2002
    ..However, the body of clinical evidence is currently not sufficient to recommend rhG-CSF or rhGM-CSF administration confidently as routine adjunctive treatment for neonates with sepsis...
  8. ncbi Use of hematopoietic growth factors in elderly patients receiving cytotoxic chemotherapy
    C Bokemeyer
    Abteilung Hamatologie, Onkologie, Rheumatologie und Immunologie, Medizinische Universitätsklinik Tübingen, Germany
    Onkologie 25:32-9. 2002
    ....
  9. ncbi The role of colony-stimulating factors and granulocyte transfusion in treatment options for neutropenia in children with cancer
    Der Cherng Liang
    Division of Hematology Oncology, Department of Pediatrics, Mackay Memorial Hospital, Taipei, Taiwan
    Paediatr Drugs 5:673-84. 2003
    ..Granulocyte transfusion has shown promising results in treating children with severe neutropenic infection; however, controlled trials are warranted to clarify the efficacy and cost-effectiveness of this procedure...
  10. ncbi Notch ligands, Delta-1 and Delta-4 suppress the self-renewal capacity and long-term growth of two myeloblastic leukemia cell lines
    Shuji Tohda
    Department of Laboratory Medicine, Tokyo Medical and Dental University, Tokyo 113 8519, Japan
    Int J Oncol 22:1073-9. 2003
    ..If the Notch system in AML cells is precisely understood, the control of Notch activation will become a novel therapeutic approach for AML...
  11. ncbi Large volume leukapheresis in small children: safety profile and variables affecting peripheral blood progenitor cell collection
    J Sevilla
    Hospital Infantil Universitario Nino Jesus, Madrid, Spain
    Bone Marrow Transplant 31:263-7. 2003
    ..0001). In all, 77% of patients achieved the target CD34(+) cell dose of 2 x 10(6)/kg in their first apheresis. Recruitment was seen in 72% of the procedures, and this was related to the total blood volume processed (P=0.0005)...
  12. ncbi Generation of antigen-loaded dendritic cells in a serum-free medium using different cytokine combinations
    Tomas Buchler
    Department of Clinical Hematology, Masaryk University Hospital, Brno, Czech Republic
    Vaccine 21:877-82. 2003
    ..The cultured cells expressed the mature immunophenotype. No significant differences in cell yield or immunophenotype were detected when comparing different cytokine combinations...
  13. ncbi A phase I study of the GM-CSF antagonist E21R
    Ian N Olver
    Royal Adelaide Hospital Cancer Centre, North Terrace, Adelaide, South Australia 5000, Australia
    Cancer Chemother Pharmacol 50:171-8. 2002
    ..E21R is a competitive inhibitor of GM-CSF. This is the initial clinical study to investigate the safety, toxicity and pharmacokinetics of escalating doses of E21R...
  14. ncbi Hematopoietic management in oncology practice. Part 1. Myeloid growth factors
    John A Glaspy
    Division of Hematology Oncology, UCLA School of Medicine, Los Angeles, California, USA
    Oncology (Williston Park) 17:1593-603. 2003
    ..In randomized trials, rhG-CSF has consistently decreased the duration of neutropenia during all cycles of chemotherapy and reduced the risk of infection by 50% or more. Trials of rhGM-CSF have not reported consistent results...
  15. ncbi Infusion of unpulsed dendritic cells derived from granulocyte/macrophage colony-stimulating factor-mobilized peripheral blood CD34+ cells and monocytes in patients with advanced carcinoma
    Pierre L Triozzi
    The Arthur G James Cancer Hospital, The Ohio State University Comprehensive Cancer Center, Columbus, OH 43210, USA
    J Hematother Stem Cell Res 12:279-87. 2003
    ..The infusion of these dendritic cells has nonspecific immunomodulatory activity that may have clinical significance...
  16. ncbi [Rational therapy with hematopoetic growth factors (G-CSF, GM-CSF) for patients in neutropenia]
    C Kahl
    Abteilung Hämatologie und Onkologie, Klinik und Poliklinik für Innere Medizin, Universitat Rostock, Germany
    Dtsch Med Wochenschr 127:1473-8. 2002
  17. ncbi Regulatory balance between the immune response of tumor antigen-specific T-cell receptor gene-transduced CD8 T cells and the suppressive effects of tolerogenic dendritic cells
    Shin ichiro Fujii
    Research Unit for Cellular Immunotherapy, Research Center for Allergy and Immunology RCAI, RIKEN, Yokohama, Kanagawa 230 0045, Japan
    Cancer Sci 96:897-902. 2005
    ....
  18. ncbi [Hematopoietic growth factors and autologous or allogeneic stem cell transplantation]
    Jacques Olivier Bay
    Unité de Transplantation Médullaire, Centre Jean Perrin, 58, rue Montalembert, 63000 Clermont Ferrand
    Bull Cancer 93:473-82. 2006
    ..The new long acting growth factors such as pegfilgrastim are still under evaluation and their use in mobilization seems promising...
  19. ncbi MHC II+ CD45+ cells from synovium-rich tissues of normal rats: phenotype, comparison with macrophage and dendritic cell lineages and differentiation into mature dendritic cells in vitro
    Mahin Moghaddami
    Arthritis Research Laboratory, Hanson Institute for Medical Research, Institute of Medical and Veterinary Science, Adelaide, South Australia
    Int Immunol 17:1103-15. 2005
    ..These results demonstrate that SRTs contain indeterminate cells that can differentiate into mature DCs in vitro in response to GM-CSF, plus mature synovial lining macrophages...
  20. ncbi Clinical use of subcutaneous G-CSF or GM-CSF in malignancy
    Mary L Disis
    Center for Translational Medicine in Women s Health, University of Washington, Seattle, Washington 91809, USA
    Oncology (Williston Park) 19:5-9. 2005
  21. ncbi [Recommendation for using granulocyte and granulocyte-macrophage growth factor during anti-cancer therapy in children]
    Walentyna Balwierz
    Klinika Onkologii i Hematologii, Polsko Amerykanskiego Instytutu Pediatrii, Collegium Medicum, Uniwersytetu Jagiellohrskiego w Krakowie
    Przegl Lek 63:1-6. 2006
    ....
  22. ncbi Dendritic cells: emerging roles in tumor immunotherapy
    Patricia C Buchsel
    College of Nursing, Seattle University, Washington, USA
    Clin J Oncol Nurs 10:629-40. 2006
    ..Oncology nurses need to be knowledgeable regarding new therapies. Using knowledge gained through reading professional journals and self-education, nurses can inform patients of new therapies, which may increase patients' hope...
  23. ncbi [In vitro cultivation of dendritic cells with serum-free medium]
    Huai Dong Zhang
    Department of Hematology, Shanton Central Hospital, Shanton 310003, China
    Zhongguo Shi Yan Xue Ye Xue Za Zhi 14:985-9. 2006
    ..DC cultured and induced by serum-free medium is worth using in practice widely...
  24. ncbi A randomized trial comparing the combination of granulocyte-macrophage colony-stimulating factor plus granulocyte colony-stimulating factor versus granulocyte colony-stimulating factor for mobilization of dendritic cell subsets in hematopoietic progenitor
    Sagar Lonial
    Winship Cancer Institute, Emory University School of Medicine, 1365 Clifton Road, Atlanta, GA 30322, USA
    Biol Blood Marrow Transplant 10:848-57. 2004
    ....
  25. ncbi [In vitro anti-tumor effect of CTL induced by HSP70-Id complex-modified dendritic cells]
    Zhi Hua Wang
    Department of Urology, Tongii Hospital, Tongji Medical College of Huazhong University of Science and Technology, Wuhan 430030, China
    Zhonghua Zhong Liu Za Zhi 28:481-5. 2006
    ....
  26. ncbi TGFbeta-dependent gene expression profile during maturation of dendritic cells
    O Fainaru
    Department of Molecular Genetics, Weizmann Institute of Science, Rehovot, Israel
    Genes Immun 8:239-44. 2007
    ..This finding supports the possibility that TGFbeta-dependent inhibition of CCR7 expression in DC is mediated by PPARgamma...
  27. pmc Inflammation-associated cell cycle-independent block of apoptosis by survivin in terminally differentiated neutrophils
    Frank Altznauer
    Dept of Pharmacology, University of Bern, Friedbuhlstrasse 49, CH 3010 Bern, Switzerland
    J Exp Med 199:1343-54. 2004
    ..These data provide new insights into the regulation and function of survivin and have important implications for the pathogenesis, diagnosis, and treatment of inflammatory diseases and cancer...
  28. ncbi Influence of preapheresis clinical factors on the efficiency of CD34+ cell collection by large-volume apheresis
    C Sarkodee-Adoo
    University of Maryland School of Medicine, Greenebaum Cancer Center, Baltimore, MD, USA
    Bone Marrow Transplant 31:851-5. 2003
    ..Leukapheresis appears to be safe and efficient for autologous blood and marrow transplantation patients with hematocrit >27% and platelet count >30 000/microl...
  29. ncbi Harvesting peripheral blood stem cells from healthy donors on 4th day of cytokine mobilization
    Sang Kyun Sohn
    Department of Hematology Oncology, Kyungpook National University Hospital, Daegu, South Korea
    J Clin Apher 18:186-9. 2003
    ....
  30. ncbi Mobilizing stem cells from normal donors: is it possible to improve upon G-CSF?
    A F Cashen
    Department of Medicine, Washington University School of Medicine, St Louis, MO, USA
    Bone Marrow Transplant 39:577-88. 2007
    ..Here, we review the current state of stem cell mobilization in normal donors and discuss novel strategies for donor stem cell mobilization...
  31. ncbi Immunomodulation, part II: granulocyte colony-stimulating factors
    Susan Givens Bell
    University of South Florida, Tampa, USA
    Neonatal Netw 25:65-70. 2006
    ..The next part of this series will explore the use of intravenous immunoglobulins to prevent and treat neonatal sepsis...
  32. ncbi Hemophagocytosis exacerbated by G-CSF/GM-CSF treatment in a patient with myelodysplasia
    Sa Wang
    Department of Pathology, Yale University School of Medicine, New Haven, Connecticut, USA
    Am J Hematol 77:391-6. 2004
    ..We propose that myeloid growth factors may be detrimental in patients with MDS-associated hemophagocytosis...
  33. ncbi Engraftment syndrome after autologous hematopoietic stem cell transplant supported by granulocyte-colony-stimulating factor (G-CSF) versus granulocyte-macrophage colony-stimulating factor (GM-CSF)
    M Akasheh
    Department of Medicine, Medical College of Wisconsin, Milwaukee, WI 53226, USA
    Bone Marrow Transplant 31:113-6. 2003
    ..It suggests that it might be advantageous to administer only G-CSF in breast cancer patients undergoing AHSCT to reduce ES-related morbidity...
  34. ncbi The effect of leptin on engraftment in patients undergoing peripheral blood stem cell transplantation
    Selmin Ataergin
    Department of Internal Medicine, Bone Marrow Transplantation Center, Gulhane School of Medicine, 06018 Etlik Ankara, Turkey
    Haematologia (Budap) 32:389-96. 2002
    ..Thirty-two patients (19 male, 13 female) with various hematological and solid tumors and 28 healthy subjects (15 male, 13 female) as a control group were enrolled in the study...
  35. ncbi Eicosapentaenoic acid inhibits CSF-induced human monocyte survival and maturation into macrophage through the stimulation of H2O2 production
    Sachiyo Terada
    Division of Clinical Nutrition, National Institute of Health and Nutrition, Tokyo, Japan
    J Leukoc Biol 71:981-6. 2002
    ..Such an apoptosis inducing effect on monocytes by EPA may contribute to the efficacy of EPA in atherosclerosis and autoimmune diseases...
  36. ncbi C-kit positive porcine bone marrow progenitor cells identified and enriched using recombinant stem cell factor
    Artur Summerfield
    Institute of Virology and Immunoprophylaxis, Sensemattstrasse 293, CH 3147 Mittelhäusern, Switzerland
    J Immunol Methods 280:113-23. 2003
    ..Using magnetic or fluorescence-activated cell sorting, SCF-ligating BMHC were enriched for pluripotent progenitor cells. In this manner, porcine haematological studies can be pursued in a detailed manner not before possible...
  37. ncbi Immature dendritic cells (CD11c+ CD3- B220- cells) present in mouse peripheral blood
    Yasushi Adachi
    First Department of Pathology, Kansai Medical University, Moriguchi City, Osaka, Japan
    Immunobiology 206:354-67. 2002
    ..Moreover, they migrate into the spleen when they are injected intravenously. These results suggest that CD11c+ CD3- B220- cells in the PBMCs are immature DCs, and that they migrate into the spleen, where they mature...
  38. ncbi Selective induction of dendritic cells using granulocyte macrophage-colony stimulating factor, but not fms-like tyrosine kinase receptor 3-ligand, activates thyroglobulin-specific CD4+/CD25+ T cells and suppresses experimental autoimmune thyroiditis
    Chenthamarakshan Vasu
    Department of Surgery, University of Illinois, Chicago, IL 60612, USA
    J Immunol 170:5511-22. 2003
    ..These results indicate that skewing immune response toward Th2, through selective activation of dendritic cells using GM-CSF, may have therapeutic potential in Th1 dominant autoimmune diseases including Hashimoto's thyroiditis...
  39. pmc Critical roles of interferon regulatory factor 4 in CD11bhighCD8alpha- dendritic cell development
    Shoichi Suzuki
    Department of Host Defense Biochemistry, Institute of Tropical Medicine, Graduate School of Biomedical Sciences, Nagasaki University, 1 12 4 Sakamoto, Nagasaki 852 8523, Japan
    Proc Natl Acad Sci U S A 101:8981-6. 2004
    ..These results imply that IRF-4 and IRF-8 selectively play critical roles in the development of the DC subsets that express them...
  40. ncbi Oxygen tension regulates the in vitro maturation of GM-CSF expanded murine bone marrow dendritic cells by modulating class II MHC expression
    Samuel R Goth
    NIEHS Center for Children s Environmental Health, University of California at Davis, Davis, CA 95616, USA
    J Immunol Methods 308:179-91. 2006
    ..The O2 tension (but not 2-Me addition) in vitro significantly influences overall DC subset frequencies and yield, and governs DC maturation by regulating the surface class II MHC expression of GM-CSF expanded BMDC cultures...
  41. ncbi The interaction of human dendritic cells with yeast and germ-tube forms of Candida albicans leads to efficient fungal processing, dendritic cell maturation, and acquisition of a Th1 response-promoting function
    G Romagnoli
    Department of Infectious, Parasitic and Immune Mediated Diseases, Istituto Superiore di Sanita, Rome, Italy
    J Leukoc Biol 75:117-26. 2004
    ..albicans, both seemingly activating the Th1-type immunity which is characteristic of the healthy human subjects, naturally immunized and protected against the fungus...
  42. ncbi Analysis of dendritic cell trafficking using EGFP-transgenic mice
    Andreas A O Eggert
    Tumor Immunology Laboratory, University Medical Center Nijmegen St Radboud, P O Box 9101, 6500 HB Nijmegen, The Netherlands
    Immunol Lett 89:17-24. 2003
    ..c. injection. Subsequent quantitative, phenotypical and ultrastuctural analysis demonstrate that DC generated from EGFP-transgenic mice are well suited to study the migratory behavior, distribution and phenotype of DC in vivo...
  43. ncbi Cyclosporine preconditions dendritic cells during differentiation and reduces IL-2 and IL-12 production following activation: a potential tolerogenic effect
    D Sauma
    Departmento de Biologia, Facultad de Ciencias, Universidad de Chile, Santiago, Chile
    Transplant Proc 35:2515-7. 2003
    ..These results may be especially meaningful for the future design of immunosuppressive protocols...
  44. ncbi Chemokine receptor CCR7 induces intracellular signaling that inhibits apoptosis of mature dendritic cells
    Noelia Sanchez-Sanchez
    Centro de Investigaciones Biologicas, Consejo Superior de Investigaciones Cientificas, Madrid, Spain
    Blood 104:619-25. 2004
    ..In summary, in addition to its well-established role in chemotaxis, we show that CCR7 also induces antiapoptotic signaling in mature DCs...
  45. ncbi [Effect of tumor antigen specific CTL induced by dendritic cells on a model of human hepatocellular carcinoma in nude mice (LCI-D20)]
    Guo Lin Chen
    Institute for Viral Hepatitis, Chongqing University of Medical Sciences, Chongqing 400010, China
    Zhonghua Gan Zang Bing Za Zhi 14:431-4. 2006
    ..To investigate the cure effect of tumor antigen specific CTL on a model of human hepatocellular carcinoma in nude mice LCI-D20...
  46. ncbi [In vitro culture and identification of tolerogenic dendritic cells from mouse bone marrow]
    Chun Yu Gu
    Department of Clinical Laboratory, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China
    Di Yi Jun Yi Da Xue Xue Bao 25:959-62. 2005
    ..To establish a simple and economic method for in vitro culture of tolerogenic dendritic cells (Tol-DC) from mouse bone marrow to facilitate further research of the application of Tol-DC in autoimmune disease...
  47. ncbi Therapeutic effect of alpha-galactosylceramide-loaded dendritic cells genetically engineered to express SLC/CCL21 along with tumor antigen against peritoneally disseminated tumor cells
    Hidetake Matsuyoshi
    Department of Immunogenetics, Graduate School of Medical Sciences, Kumamoto University, 1 1 1 Honjo, Kumamoto 860 8556, Japan
    Cancer Sci 96:889-96. 2005
    ..The present study suggests a novel way to use alpha-GalCer in immunotherapy for peritoneally..
  48. ncbi Actions and therapeutic potential of G-CSF and GM-CSF in cardiovascular disease
    Jason C Kovacic
    Victor Chang Cardiac Research Institute, Sydney, Australia
    J Mol Cell Cardiol 42:19-33. 2007
    ....
  49. ncbi Clinical and immunological characteristics of patients with serologic progression of prostate cancer achieving long-term disease control with granulocyte-macrophage colony-stimulating factor
    Brian I Rini
    University of California San Francisco Comprehensive Cancer Center, San Francisco, California, USA
    J Urol 175:2087-91. 2006
    ..We describe the clinical and immunological characteristics of patients with biochemically relapsed prostate cancer who achieved long-term disease control with GM-CSF (Leukine)...
  50. ncbi Release of PEGylated granulocyte-macrophage colony-stimulating factor from chitosan/glycerol films
    C D Brown
    University of Washington, Department of Bioengineering, Box 352255, Seattle, WA 98195, USA
    J Control Release 72:35-46. 2001
    ....
  51. ncbi Induction of HIV-1-specific cellular and humoral immune responses following immunization with HIV-DNA adjuvanted with activated apoptotic lymphocytes
    Andreas Brave
    Department of Microbiology Tumor and Cell Biology, Karolinska Institutet, Sweden
    Vaccine 28:2080-7. 2010
    ..These data suggest that activated apoptotic lymphocytes can act independent as adjuvants to improve antigen-specific DNA vaccines...
  52. pmc Transduction of nondividing human macrophages with gammaretrovirus-derived vectors
    Loraine Jarrosson-Wuilleme
    LaboRetro, INSERM U412, Ecole Normale Superieure de Lyon, IFR 128 Biosciences Lyon Gerland, 46 allee d Italie, 69364 Lyon, France
    J Virol 80:1152-9. 2006
    ..This finding suggests that factors other than the nuclear membrane govern permissiveness to gammaretroviral infection and raises the possibility of using the macrophage tropism of F-MLV in gene therapy...
  53. ncbi [Rapid serum-free culture of dendritic cells from human peripheral blood monocytes and their intracellular signal transduction]
    Jun Wu
    Department of Immunology, Southern Medical University, Guangzhou 510515, China
    Di Yi Jun Yi Da Xue Xue Bao 24:1263-6. 2004
    ....
  54. ncbi Treatment of Behçet's disease--an update
    V G Kaklamani
    Newton Wellesley Hospital, Boston, MA, USA
    Semin Arthritis Rheum 30:299-312. 2001
    ..With proper management of BD, loss of useful vision was reduced from 75% to 20% of the affected eyes. However, less favorable results are seen for central nervous system and large artery and vein involvement...
  55. ncbi Granulocyte/macrophage-colony stimulating factor produced by recombinant avian poxviruses enriches the regional lymph nodes with antigen-presenting cells and acts as an immunoadjuvant
    E Kass
    Laboratory of Tumor Immunology and Biology, National Cancer Institute, NIH, Bethesda, Maryland 20892, USA
    Cancer Res 61:206-14. 2001
    ....
  56. ncbi Multi-subtype gp160 DNA immunization induces broadly neutralizing anti-HIV antibodies
    E Rollman
    Department of Virology, Swedish Institute for Infectious Disease Control and Microbiology and Tumor Biology Center, Karolinska Institutet, Stockholm, Sweden
    Gene Ther 11:1146-54. 2004
    ..Moreover, it documents the ability of rGM-CSF to enhance the potency of such a vaccine when given simultaneously. The strategy may be useful for making an HIV vaccine more potent and broadly effective against strains of different clades...
  57. ncbi GM-CSF-secreting cancer immunotherapies: preclinical analysis of the mechanism of action
    Andrew D Simmons
    Cell Genesys Inc, 500 Forbes Blvd, South San Francisco, CA, 94080, USA
    Cancer Immunol Immunother 56:1653-65. 2007
    ..Taken together, these studies provide important new insights into the mechanism of action of this promising novel cancer immunotherapy...
  58. ncbi Granulocyte macrophage colony-stimulating factor and interleukin-5 activate STAT5 and induce CIS1 mRNA in human peripheral blood eosinophils
    S Bhattacharya
    Department of Pathology and Laboratory Medicine, University of Wisconsin Medical School, Madison, Wisconsin 53792, USA
    Am J Respir Cell Mol Biol 24:312-6. 2001
    ..These data suggest that active nuclear STAT5 participates in the regulation of IL-5 and GM-CSF--inducible genes in stimulated human peripheral blood eosinophils...
  59. ncbi Immune-stimulating effects of low-dose perioperative recombinant granulocyte-macrophage colony-stimulating factor in patients operated on for primary colorectal carcinoma
    A K Mels
    Department of Surgery, Academic Hospital, Vrije Universiteit, Amsterdam, The Netherlands
    Br J Surg 88:539-44. 2001
    ..The implications for the antitumour responses directly after operation and the formation of liver metastases are currently under investigation...
  60. ncbi A clinical trial of edrecolomab, interleukin-2 and GM-CSF in patients with advanced colorectal cancer
    W Fiedler
    Department of Oncology Hematology, University Hospital Eppendorf, Hamburg, Germany
    Oncol Rep 8:225-31. 2001
    ..No partial or complete responses were observed in these 12 patients. Median time to treatment failure was 67 days and median survival 287 days. Immunological parameters were monitored throughout the study...
  61. ncbi A randomized trial of granulocyte-macrophage colony-stimulating factor in neonates with sepsis and neutropenia
    K Bilgin
    Department of Pediatrics, Dicle Medical School, Diyarbakir, Turkey
    Pediatrics 107:36-41. 2001
    ....
  62. ncbi Tumor-related immunity in prostate cancer patients treated with human recombinant granulocyte monocyte-colony stimulating factor (GM-CSF)
    Thomas Schwaab
    Uro oncology Group, Norris Cotton Cancer Center NCCC at Dartmouth Hitchcock Medical Center DHMC, NH, Lebanon
    Prostate 66:667-74. 2006
    ..We hypothesized that systemic therapy with GM-CSF in prostate cancer patients could augment prostate cancer-related immunity and induce clinical response...
  63. ncbi A human monoclonal IgG1 potently neutralizing the pro-inflammatory cytokine GM-CSF
    Eva Maria Krinner
    Micromet AG, Staffelseestr 2, D 81477 Munich, Germany
    Mol Immunol 44:916-25. 2007
    ..Based on its favorable properties, MT203 has been selected for development as a novel anti-inflammatory human monoclonal antibody with therapeutic potential in a multitude of human autoimmune and inflammatory diseases...
  64. ncbi Can 29kDa rhGM-CSF expressed by silkworm pupae bioreactor bring into effect as active cytokine through orally administration?
    Yaozhou Zhang
    Institute of Biochemistry, Zhejiang Sci Tech University, Hangzhou 310018, China
    Eur J Pharm Sci 28:212-23. 2006
    ..These results proved that BmrhGM-CSF, a 29kDa glycoprotein expressed by Silkworm pupae bioreactor, could bring into the effect as active cytokine through oral administration...
  65. ncbi Prostaglandin E2 is generally required for human dendritic cell migration and exerts its effect via EP2 and EP4 receptors
    Daniel F Legler
    Biotechnology Institute Thurgau, Tägerwilen, Switzerland
    J Immunol 176:966-73. 2006
    ..Our results provide clear evidence that PGE2 is a general and mandatory factor for the development of a migratory phenotype of human MoDCs as well as for peripheral blood myeloid DCs...
  66. ncbi Characterization of poly(glycolide-co-D,L-lactide)/poly(D,L-lactide) microspheres for controlled release of GM-CSF
    D K Pettit
    Department of Analytical Chemistry and Formulation, Immunex Corporation, Seattle, Washington 98101, USA
    Pharm Res 14:1422-30. 1997
    ....
  67. ncbi HIV integration site selection: targeting in macrophages and the effects of different routes of viral entry
    Stephen D Barr
    Department of Microbiology, University of Pennsylvania School of Medicine, 3610 Hamilton Walk, Philadelphia, 19104 6076, USA
    Mol Ther 14:218-25. 2006
    ..Analysis of additional published integration site sequences also indicated that the route of entry did not affect integration site selection for other viral envelopes as well...
  68. ncbi Versican is induced in infiltrating monocytes in myocardial infarction
    Kenichi Toeda
    Department of Medicine and Medical Science, Okayama University Graduate School of Medicine and Dentistry, Japan
    Mol Cell Biochem 280:47-56. 2005
    ..We suggest that upregulation of versican in the infarcted myocardium may have a role in the inflammatory reaction, which mediates subsequent chemotaxis in the infarcted heart...
  69. ncbi Differential expression of IFN regulatory factor 4 gene in human monocyte-derived dendritic cells and macrophages
    Anne Lehtonen
    Department of Viral Diseases and Immunology, National Public Health Institute, Helsinki, Finland
    J Immunol 175:6570-9. 2005
    ..Our results suggest that IRF4 is likely to play an important role in myeloid DC differentiation and gene regulatory functions...
  70. ncbi Recombinant human granulocyte-macrophage colony stimulating factor (sargramostim) as an alternative therapy for fistulizing Crohn's disease
    Priscilla Magno
    Division of Gastroenterology and Liver Diseases, Department of Medicine, School of Medicine, Medical Sciences Campus, University of Puerto Rico, San Juan, Puerto Rico
    P R Health Sci J 29:60-5. 2010
    ....
  71. ncbi Colony-stimulating factor use in the context of refined risk and benefit assessments
    Jeffrey Crawford
    Division of Medical Oncology, Duke Comprehensive Cancer Center, Durham, North Carolina 27710 0001, USA
    Oncology (Williston Park) 20:9-10. 2006
  72. ncbi Modulation of integrin function in hematopoietic progenitor cells by CD43 engagement: possible involvement of protein tyrosine kinase and phospholipase C-gamma
    N Anzai
    Departments of Microbiology Immunology, Medicine, and the Walther Oncology Center, Indiana University School of Medicine, Indianapolis, IN, USA
    Blood 93:3317-26. 1999
    ..These results indicate that signals mediated through CD43 may increase integrin affinity to fibronectin via a pathway dependent on protein tyrosine kinase and PLC-gamma activation in hematopoietic progenitors...
  73. ncbi The safety and efficacy of granulocyte-macrophage colony-stimulating factor (Sargramostim) added to indinavir- or ritonavir-based antiretroviral therapy: a randomized double-blind, placebo-controlled trial
    G Skowron
    Division of Infectious Diseases, Roger Williams Medical Center, Providence, RI 02908, USA
    J Infect Dis 180:1064-71. 1999
    ..No difference in indinavir pharmacokinetics was observed before or after sargramostim therapy...
  74. ncbi GM-CSF activates the Jak/STAT pathway to rescue polymorphonuclear neutrophils from spontaneous apoptosis in young but not elderly individuals
    Carl F Fortin
    Department of Medicine, Research Center on Aging, Laboratory of Biogerontology, Sherbrooke Geriatric University Institute, 1036, rue Belvedere Sud, J1H 4C4 Sherbrooke, QC, Canada
    Biogerontology 8:173-87. 2007
    ....
  75. ncbi Evolving knowledge and therapy of inflammatory bowel disease
    Joshua R Korzenik
    Gastrointestinal Unit, Department of Medicine, Center for the Study of Inflammatory Bowel Disease, Massachusetts General Hospital and Harvard Medical School, 55 Fruit Street, Boston, Massachusetts 02114, USA
    Nat Rev Drug Discov 5:197-209. 2006
    ..With increasing evidence for a crucial role for luminal flora in maintaining the health of the bowel, strategies to manipulate intestinal bacteria using probiotics and prebiotics are being actively investigated as well...
  76. ncbi Combining gene and immunotherapy for prostate cancer
    J G Young
    Cancer Research UK Institute for Cancer Studies, University of Birmingham, Edgbaston, Birmingham, UK
    Prostate Cancer Prostatic Dis 11:187-93. 2008
    ..The mechanism of this improved response is however likely to be non-immune based as it lacks a memory effect...
  77. pmc Modulation of diabetes-induced palate defects by maternal immune stimulation
    Terry C Hrubec
    Department of Biomedical Sciences, E Via Virginia College of Osteopathic Medicine, 2265 Kraft Drive, Blacksburg, VA 24060, USA
    Anat Rec (Hoboken) 292:271-6. 2009
    ..Maternal immune stimulation may prevent dysregulation of these signaling pathways thus reducing fetal malformations and normalizing palate growth...
  78. ncbi Gene expression profiling and functional activity of human dendritic cells induced with IFN-alpha-2b: implications for cancer immunotherapy
    Federica Moschella
    The International Institute of Genetics and Biophysics, Naples, Italy
    Clin Cancer Res 9:2022-31. 2003
    ....
  79. pmc Immunotherapy with concurrent subcutaneous GM-CSF, low-dose IL-2 and IFN-alpha in patients with progressive metastatic renal cell carcinoma
    N Verra
    Division of Immunology, Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands
    Br J Cancer 88:1346-51. 2003
    ..Response and survival with this form of immunotherapy seem to be more dependent on expansion/activation of T cells than of NK cells...
  80. ncbi Impact of chemotherapy regimen and hematopoietic growth factor on mobilization and collection of peripheral blood stem cells in cancer patients
    M R Nowrousian
    Department of Internal Medicine Cancer Research, West German Cancer Center, University of Essen Medical School, Germany
    Ann Oncol 14:i29-36. 2003
    ....
  81. pmc Toll-like receptor-mediated activation of neutrophils by influenza A virus
    Jennifer P Wang
    Department of Medicine, University of Massachusetts Medical School, Worcester, MA 01605, USA
    Blood 112:2028-34. 2008
    ..These studies demonstrate neutrophil activation by influenza virus and highlight the importance of TLR7 and TLR8 in that response...
  82. ncbi The role of myeloid growth factors in acute leukemia
    Martha Wadleigh
    Dana Farber Cancer Institute, Boston, MA 02115, USA
    J Natl Compr Canc Netw 7:84-91. 2009
    ..This article focuses on the clinical experience with these agents as adjuncts to the treatment of acute leukemias...
  83. pmc STAT3- and STAT5-dependent pathways competitively regulate the pan-differentiation of CD34pos cells into tumor-competent dendritic cells
    Peter A Cohen
    Center for Surgery Research, Cleveland Clinic Foundation Lerner Research Institute, OH 44195, USA
    Blood 112:1832-43. 2008
    ....
  84. ncbi Granulocyte macrophage colony-stimulating factor: current practice and novel approaches
    Patricia C Buchsel
    Clin J Oncol Nurs 6:198-205. 2002
    ....
  85. ncbi Interleukin-13 induces thymus and activation-regulated chemokine (CCL17) in human peripheral blood mononuclear cells
    Tomohiro Nomura
    Department of Otorhinolaryngology J2, Graduate School of Medicine, Chiba University, 1 8 1 Inohana, Chuo Ku, Chiba, 260 0856, Japan
    Cytokine 20:49-55. 2002
    ..Thymus and activation-regulated chemokine (TARC/CCL17) is a recently identified chemokine that induces the development of Th(2) lymphocytes. One of the sources of TARC has been reported to be peripheral blood mononuclear cells (PBMCs)...
  86. ncbi Differential cytokine expression and regulation of human anti-pig xenogeneic responses by modified porcine dendritic cells
    Daniel Stuart Layton
    CSIRO, Australian Animal Health Laboratories, Geelong, Victoria, Australia
    Xenotransplantation 15:257-67. 2008
    ..Porcine dendritic cells (DC) are likely to be pivotal cells in the initiation of stimulatory and potential tolerogenic responses to xenoantigens, however, there are limited studies characterizing these antigen presenting cells...
  87. ncbi Comparison of recombinant granulocyte colony-stimulating factor, recombinant human granulocyte-macrophage colony-stimulating factor and placebo for treatment of septic preterm infants
    Asma Ahmad
    Division of Neonatology, Department of Pediatrics, Weill Medical College of Cornell University, New York City, NY, USA
    Pediatr Infect Dis J 21:1061-5. 2002
    ....
  88. ncbi Treatment of active Crohn's disease with recombinant human granulocyte-macrophage colony-stimulating factor
    Brian K Dieckgraefe
    Division of Gastroenterology, Department of Internal Medicine, Washington University School of Medicine, 660 South Euclid Avenue, Box 8124, St Louis, MO 63110, USA
    Lancet 360:1478-80. 2002
    ..Retreatment was effective, and treatment was associated with increased quality-of-life measures. GM-CSF may offer an alternative to traditional immunosuppression in treatment of Crohn's disease...
  89. ncbi [Deletion mutants of human granulocyte-macrophage colony-stimulating factor]
    L E Petrovskaia
    Shemyakin Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, ul Miklukho Maklaya 16 10, GSP Moscow, 117997 Russia
    Bioorg Khim 28:440-6. 2002
    ..A decrease in the mutant activity in the row D2 > D1 > D3 implies the importance of the conserved hydrophobic residues involved in the formation of the beta-structure for the formation of the GM-CSF functional conformation...
  90. ncbi Molecular cloning, expression in Escherichia coli and production of bioactive homogeneous recombinant human granulocyte and macrophage colony stimulating factor
    Raquel Cristina Schwanke
    Centro de Pesquisas em Biologia Molecular e Funcional, Instituto Nacional de Ciência e Tecnologia em Tuberculose, Pontificia Universidade Catolica do Rio Grande do Sul PUCRS, Porto Alegre RS 90619 900, Brazil
    Int J Biol Macromol 45:97-102. 2009
    ..The results presented show that the combination of experimental strategies employed to obtain recombinant hGM-CSF can yield biologically active protein, and may be useful to scaling-up production of biosimilar protein...
  91. ncbi [Construction and identification of recombinant Lactococcus lactis highly expressing human granulocyte-macrophage colony stimulating factor]
    Gao feng Ma
    Institute of Digestive Diseases, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China
    Nan Fang Yi Ke Da Xue Xue Bao 28:576-8. 2008
    ..To transfer human granulocyte-macrophage colony stimulating factor (hGM-CSF) gene into Actococcus lactis and obtain recombinant Lactococcus lactis highly expressing hGM-CSF (LL-CSF)...
  92. ncbi Extracorporeal photopheresis and adjuvant aerosolized granulocyte-macrophage colony-stimulating factor for Sézary syndrome
    Saskia A Bouwhuis
    Department of Dermatology, Mayo Clinic, Rochester, Minn 55905, USA
    Mayo Clin Proc 77:197-200. 2002
    ..It produced clinical improvement and decreased the number of circulating Sézary cells in a previously ECP-refractory patient...
  93. ncbi Granulocyte/macrophage-colony stimulating factor and interleukin-4 expand and activate type-1 dendritic cells (DC1) when administered in vivo to cancer patients
    Sylvia M Kiertscher
    Division of Pulmonary and Critical Care Medicine, UCLA School of Medicine, Los Angeles, CA 90095 1690, USA
    Int J Cancer 107:256-61. 2003
    ..These effects correlate with antigen-presenting activity, providing a mechanism by which systemic GM-CSF and IL-4 might stimulate anti-tumor immunity in vivo...
  94. ncbi Calcium channel blockers suppress cytokine-induced activation of human neutrophils
    Etsuko Shima
    Department of Physiology, Osaka City University Medical School, Asahi machi, Abeno Ku, Osaka, Japan
    Am J Hypertens 21:78-84. 2008
    ..Calcium channel blockers are commonly used in the treatment of hypertension, and their pleiotropic effects, other than the lowering of blood pressure, have been recently recognized...
  95. ncbi [Cost effectiveness of GM-CSF in the treatment of acute myeloblastic leukemia in aged patients: protocol of GOELAM Sa3]
    M C Woronoff-Lemsi
    Pharmacie, , Bd Fleming, , France
    Therapie 56:131-3. 2001
    ..In the younger patient group savings were synonymous with GM-CSF. In all cases GM-CSF strategy induced benefit expressed as savings as well as efficacy...
  96. ncbi Big tumor regression induced by GM-CSF gene-modified 3LL tumor cells via facilitating DC maturation and deviation toward CD11c+CD8alpha+ subset
    Yi Lin
    Department of Immunology, Institute for Immunobiology, Shanghai Medical College of Fudan University, Shanghai, P R China
    DNA Cell Biol 26:863-72. 2007
    ..Our research indicated that GM-CSF could optimize the immune microenvironment in the tumor site, which provides a potent approach for immunotherapy of tumors...
  97. ncbi Modeling the functional heterogeneity of leukemia stem cells: role of STAT5 in leukemia stem cell self-renewal
    Michael Heuser
    Terry Fox Laboratory, British Columbia Cancer Agency, Vancouver, BC, V5Z 1L3 Canada
    Blood 114:3983-93. 2009
    ..Our data demonstrate the functional heterogeneity of LICs and show that STAT signaling is critical for leukemia stem cell self-renewal in MN1- and HOXA9-expressing leukemias...
  98. ncbi Steroid-sparing properties of sargramostim in patients with corticosteroid-dependent Crohn's disease: a randomised, double-blind, placebo-controlled, phase 2 study
    J F Valentine
    Gastroenterology, Hepatology and Nutrition, University of Florida, 1600 SW Archer Rd, Rm HD 602, Gainesville, FL 32610, USA
    Gut 58:1354-62. 2009
    ..This randomised clinical trial evaluated the efficacy of recombinant human granulocyte-macrophage colony-stimulating factor (sargramostim), an activator of innate immunity, in corticosteroid-dependent patients with Crohn's disease...
  99. ncbi The efficient generation of immunocompetent dendritic cells from leukemic blasts in acute myeloid leukemia: a local experience
    Kambiz Bagheri
    Department of Immunology, Faculty of Medical Sciences, Tarbiat Modares University, P O Box 14115 331, Tehran, Iran
    Pathol Oncol Res 15:257-67. 2009
    ..Our data confirmed the generation of sufficient AML-derived cells with the properties of DCs in all cases. This potency of AML blasts, offers a useful route for active immunotherapy of AML patients...
  100. ncbi GM-CSF plus rituximab immunotherapy: translation of biologic mechanisms into therapy for indolent B-cell lymphomas
    Stephen J Schuster
    Department of Medicine, Hematology Oncology Division, Hospital of the University of Pennsylvania, Philadelphia, PA, USA
    Leuk Lymphoma 49:1681-92. 2008
    ..The biologic effects of these individual and combined immunotherapeutic agents, with or without chemotherapy, and their translation into patient outcomes are reviewed here...
  101. pmc A dose-escalation study of aerosolized sargramostim in the treatment of metastatic melanoma: an NCCTG Study
    Svetomir N Markovic
    Melanoma Study Group, Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA
    Am J Clin Oncol 31:573-9. 2008
    ..To improve the clinical and immunologic efficacy of therapy without compromising patient safety, we performed a further dose escalation trial in patients with metastatic melanoma...

Research Grants34

  1. B7-DC Cross-linking antibody immunotherapy
    Svetomir Markovic; Fiscal Year: 2008
    ..If successful, this "proof-of-principle" clinical trial will justify further development of B7-DC XAb as a cancer therapeutic with potential universal application for all malignant disorders. [unreadable] [unreadable] [unreadable]..
  2. Proteomic Analysis of Diabetic Nephropathy
    Jon Klein; Fiscal Year: 2003
    ..abstract_text> ..
  3. Multi-Antigen Vaccines for Breast Cancer
    MARY DISIS; Fiscal Year: 2007
    ..abstract_text> ..
  4. Pseudovirion Formation by Live Vector HIV Vaccines
    Paul Spearman; Fiscal Year: 2007
    ..Together, these experiments will provide important insights into the role of pseudovirions in generating HIV-specific immune responses following live vector immunization. [unreadable] [unreadable]..
  5. Separating Antitumor & GvHD in Allogeneic T-Cells
    EDMUND WALLER; Fiscal Year: 2007
    ..Our studies will improve the understanding of the role of donor cells in inducing GvHD and GvT effects after allogeneic HPCT and facilitate development of novel approaches in immunotherapy cancer patients. ..
  6. CD4 Immune Reconstitution in SIV Infection
    Francois Villinger; Fiscal Year: 2007
    ..Results of these studies will form the basis for future immune reconstitution strategies in human HIV infected patients. ..
  7. Vector-based Generation of Monoclonal Antibodies against the CB2 Receptor
    Michael Roth; Fiscal Year: 2007
    ..This work has the capacity to significantly accelerate cannabinoid research. [unreadable] [unreadable] [unreadable]..
  8. Therapeutic Modulation of COX-2-induced Immunosuppression in Metastatic RCC
    Brian Rini; Fiscal Year: 2008
    ..This project will have broad implications for the immunoregulation of cancer and how expression and modulation of COX-2 expression influences the immune response to cancer. [unreadable] [unreadable] [unreadable]..
  9. Macrophage defense againt M. tuberculosis
    Jennifer Wang; Fiscal Year: 2008
    ..abstract_text> ..
  10. CYTOKINES AS PREDICTORS OF DISEASE PROGRESSION IN SCLERODERMA LUNG DISEASE
    Michael Roth; Fiscal Year: 2009
    ..It will also allow us to develop biologic markers and predictors of disease progression and to determine which patients would benefit most from treatment with cytotoxic therapy. ..
  11. Viral and Cellullar Determinants of HIV-1 Assembly
    Paul W Spearman; Fiscal Year: 2010
    ..Together, these experiments will provide important new insights into the interaction of HIV structural proteins with cellular transport pathways. ..
  12. Mechanisms of immunomodulatory and anti-tumor actions of Polysaccharide Krestin
    Mary L Disis; Fiscal Year: 2010
    ..Results from these studies will help us understand the immune modulating effect of PSK and contribute to the clinical translation of this CAM molecule as an anti-cancer agent and/or a vaccine adjuvant. ..
  13. Planning Grant for Institutional Clinical and Translational Science Award
    MARY DISIS; Fiscal Year: 2006
    ..unreadable] [unreadable] [unreadable]..
  14. Development of Enhanced HIV-1 Pseudovirion Vaccines
    Paul Spearman; Fiscal Year: 2006
    ..abstract_text> ..
  15. MIDCAREER INVESTIGATOR AWARD IN PATIENT ORIENTED RESEARC
    MARY DISIS; Fiscal Year: 2004
    ....
  16. HER2 VACCINATION FOR THE TREATMENT OF CANCER
    MARY DISIS; Fiscal Year: 2004
    ....
  17. Adjuvant immunotherapy for non-small cell lung cancer
    Michael Roth; Fiscal Year: 2005
    ..abstract_text> ..
  18. CELLULAR IMMUNOTHERAPY FOR HEMATOLOGIC MALIGNANCY
    John Levine; Fiscal Year: 2006
    ..2A. To evaluate a panel of cytokines as surrogate markers for GVHD and correlate these with clinical outcomes during the above trial. 2B. To correlate changes in minimal residual disease with clinical outcomes during the above trial. ..
  19. MARROW REGULATION IN CYCLIC HEMATOPOIESIS
    David Dale; Fiscal Year: 2003
    ....
  20. COCAINE SMOKING EFFECTS ON LUNG IMMUNITY & HOST DEFENSE
    Michael Roth; Fiscal Year: 2006
    ..abstract_text> ..
  21. Immunologic Correlates of Immunization for Cancer
    MARY DISIS; Fiscal Year: 2006
    ..abstract_text> ..
  22. Novel FRET-based Assays for HIV Assembly Inhibitors
    Paul Spearman; Fiscal Year: 2004
    ..These assays will be used to screen libraries of compounds available from NIH, Vanderbilt, and industrial partners to identify candidate inhibitors of Gag-Gag interactions. ..
  23. NK CELL ADCC AND CD4+ CELL APOPTOSIS IN HIV+ TISSUES
    Gail Skowron; Fiscal Year: 2003
    ..These relationships will be evaluated in the context of the clinical status of each patient group to be studied, and in comparison to HIV-uninfected subjects. ..
  24. Pulmonary and Immunologic Effects of Marijuana Use on HIV and Viral Immunity
    Michael D Roth; Fiscal Year: 2010
    ..These findings will help define the interrelationships between MJ abuse and opportunistic infections and provide insight into the appropriate design/use of future HIV and HBV vaccine strategies. ..
  25. PROTEOMIC ANALYSIS OF HIPPOCAMPAL HYPOXIC VULNERABILITY
    Jon Klein; Fiscal Year: 2003
    ..These studies will characterize changes in protein expression and post-translational modifications that may have important implications for cell survival and/or adaption to intermittent and sustained hypoxia. ..
  26. STUDY OF REG RECEPTOR-LIGAND BIOLOGY IN GI MUCOSA
    Brian Dieckgraefe; Fiscal Year: 2008
    ..These studies will also provide new insight into the role of Reg IV antagonists and lay the groundwork for development of therapeutic reagents active in gastrointestinal adenocarcinomas. ..
  27. Defending Against Systemic Mycoses
    GEORGE DEEPE; Fiscal Year: 2008
    ..The collaborative and synergistic effort manifested by this group of investigators will provide new and exciting information regarding prevention and/or treatment of these problematic fungi. ..
  28. Defining Neutralization Breadth in HIV+ Human Serum
    Paul W Spearman; Fiscal Year: 2010
    ..By understanding in detail the antibody responses present in these HIV-infected individuals, we will gain insights into how we can better design a protective HIV vaccine that can generate similar responses in uninfected persons. ..
  29. Novel Assays for Inhibitors of HIV Assembly
    Paul Spearman; Fiscal Year: 2007
    ..abstract_text> ..
  30. A Phase 1 Study/DNA-Based Vaccine vs Prostatic Acid Pase
    Douglas McNeel; Fiscal Year: 2006
    ..This trial will serve as a platform and model for clinical trial evaluation of antigens identified in the second aim of the proposal. ..
  31. PROTECTIVE ANTIGENS FROM HISTOPLASMA CAPSULATUM
    GEORGE DEEPE; Fiscal Year: 2007
    ..abstract_text> ..
  32. Phase I Trial of a HER2 ICD Plasmid-Based DNA Vaccine
    MARY DISIS; Fiscal Year: 2007
    ..The long-term goal will be to use this study as a platform to develop multi-antigen plasmid based vaccines for the prevention of common solid tumors. ..
  33. Acquisition of FACSVantage SE Flow Cytometer
    Yair Gazitt; Fiscal Year: 2004
    ..The new equipment will also widen the user's base, save sort time, reduce costs for users and will render sorting affordable to new users, especially in cases where low frequency (<1%) cell populations are sorted. ..